Induction of multiple drug transporters by efavirenz

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 242-250

  Weiss, Johanna ^a   Herzog, Melanie ^a   Konig, Sonja ^a   Storch, Caroline Henrike ^a   Ketabi Kiyanvash, Nahal ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Drug drug interaction; Efavirenz; Induction; Transporter

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ABC TRANSPORTER C2; ABC TRANSPORTER C3; ABC TRANSPORTER C4; ABC TRANSPORTER C5; BREAST CANCER RESISTANCE PROTEIN; EFAVIRENZ; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN SLCO2B1; PROTEIN SLCO3A1; RIFAMPICIN; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYTOCHROME P450; ORGANIC ANION TRANSPORTER;

ARTICLE; CELL INTERACTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME REGULATION; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; PROTEIN FUNCTION; CELL LINE; GENETICS; LEUKEMIA CELL LINE; METABOLISM; TIME;

ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOXAZINES; CELL LINE; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; JURKAT CELLS; ORGANIC ANION TRANSPORTERS; RNA, MESSENGER; TIME FACTORS;

EID: 65449141703     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08209FP     Document Type: Article

References (41)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 2008, January 29. pp 1-128, http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (8 April 2008, date last accessed)
2. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. New Engl J Med. 2001;344:984-996.
3. Waters L, Nelson M. Why do patients fail HIV therapy? Int J Clin Pract. 2007;61:983-990.
4. Adkins JC, Noble S. Efavirenz. Drugs. 1998;56:1055-1064.
5. Faucette S, Zhang T-C, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320:72-80.
6. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;44:1273-1281.
7. Weiss J, Weis N, Ketabi-Kiyanvash, Storch CH, Haefeli WE. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol. 2008;579:104-109.
8. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7:584-590.
9. Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and PXR. Ann Med. 2003;35:172-182.
10. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 2000;14:237-242.
11. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002;16:2295-2301.
12. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, et al. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS. 2001;27:1353-1358.
13. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999; 5:1048-1051.
14. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics. 2007;8:787-802.
15. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti- human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007;35:1853-1859.
16. Weiss J, Dormann S-MG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305:197-204.
17. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr. 2003;33:551-556.
18. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother. 2002;50:583-588.
19. Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007;60:987-993.
20. Peters T, Lindenmaier H, Haefeli WE, Weiss J. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:291-299.
21. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, et al. Expression of the drug transporters MDR1 /ABCB1, MRP1 /ABCC1, MRP2 /ABCC2, BCRP /ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 2005;70:949-958.
22. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug- sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006;34:1756-1763.
23. Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-Boosted Protease Inhibitor Monotherapy for the Treatment of HIV-1 Infection. AIDS Rev. 2008;10:4-14.
24. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P- glycoprotein. Biochem Pharmacol. 2007;73:1573-1581.
25. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76:73-84.
26. Dirson G, Fernandez C, Hindlet P, Roux F, German-Fattal M, Gimenez F, et al. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res. 2006;23:1525-1532.
27. Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ. Intracellular and plasma pharmacokinetics of efavirenz in HIV- infected individuals. J Antimicrob Chemother. 2005;56:738-744.
28. Petrick JS, Klaassen CD. Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport. Drug Metab Dispos. 2007;35:1806-1815.
29. Vyhlidal CA, Gaedigk R, Leeder JS. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos. 2006;34:131-137.
30. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet. 2003;42:1331-1357.
31. Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos. 2008;36:1172-1180.
32. Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo(a)pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis. 2005;26:1754-1763.
33. Zhang Y, Zhou G, Wang H, Zhang X, Wei F, Cai Y, et al. Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells. Oncology. 2006;71:446-455.
34. Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Szeles L, et al. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem. 2006;281:23812-23823.
35. Maggiolo F. Efavirenz. Expert Opin Pharmacother. 2007;8: 1137-1145.
36. Gerber J.G., Rosenkranz S.L., Fichtenbaum C.J., Vega J.M., Yang A., Alston B.L., et al. AIDS clinical trials group A5108 team. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS clinical trials group 5108 study. J Acquir Immune Defic Syndr. 2005;3:307-312.
37. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1 /ABCC1, MRP2/ABCC2, and MRP3 /ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos. 2007;35:340-344.
38. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, et al. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother. 2007;59: 238-245.
39. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion transporting polypeptide 2B1 is a high- affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006;80:607-620.
40. Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res. 2003;9:3052-3057.
41. Plasschaert SL, de Bont ES, Boezen M, vander Kolk DM, Daenen SM, Faber KN, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res. 2005;11:8661-8668.